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Background. The passenger leukocytes in the intes-
tine have a lineage profile that predisposes to graft-
versus-host disease (GVHD) in some animal models 
and have inferior tolerogenic qualities compared with 
the leukocytes in the liver, other solid organs, and 
bone marrow. Elimination by ex vivo irradiation of 
mature lymphoid elements from the bowel allografts is 
known to eliminate the GVHD risk. We hypothesized 
that infusion of donor bone marrow cells (BMC) in 
recipients of irradiated intestine would improve 
tolerogenesis without increasing the risk of GVHD. 
Methods. Orthotopic small intestine transplantation 
was performed with the GVHD-prone Lewis (LEW)-to-
Brown Norway (BN) combination and the reverse 
GVHD-resistant BN-to-LEW model under a short 
course of tacrolimus treatment (1 mglkglday, days 
0-13, 20, 27). Grafts were irradiated ex vivo, using a 
137CS source. In selected experimental groups, donor, 
BMC (2.5 x 108 ) were infused on the day of small intes-
tine transplantation. 
Results. The unmodified LEW intestine remained in-
tact, whether transplanted alone or with adjunct do-
nor BMC infusion, but all of the BN recipients died of 
GVHD after approximately 2 months. Intestinal graft 
irradiation (10 Gy) effectively prevented the GVHD 
and prolonged survival to 92.5 days, but all of the BN 
recipients died with chronic rejection of the LEW 
grafts, which was prevented by infusic;m of adjunct 
donor BMC without causing GVHD. In the GVHD-re-
sistant reverse strain direction (BN -"> LEW), all intes-
tinal recipients treated for 27 days with tacrolimus 
survived ~1RM days without regard for graft irradia-
tion or adjunct BMC, but chronic rejection was severe 
in the irradiated intestine, moderate in the unaltered 
graft, and least in the irradiated intestine trans-
planted with adjunct BMC. Mild arteritis in the' 150 
day allografts of both strain combinations (i.e., LEW-"> 
BN and BN ~ LEW) may have been irradiation associ-
ated, but this was prevented when weekly doses of 
tacrolimus were continued for the duration of the ex-
periment rather than being stopped at 27 days. 
Conclusions. Recipients are protected from GVHD 
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by irradiating intestinal allografts, but the resulting 
leukocyte depletion leads to chronic rejection of the 
transplanted bowel. The chronic rejection is pre-
vented with adjunct donor BMC without causing 
GVHD. Although application of the strategy may be 
limited by the possibility of radiation injury, the re-
sults are consistent with the paradigm that we have 
proposed to explain organ-induced graft acceptance, 
tolerance, and chronic rejection. 
Recent evidence has shown that passenger leukocytes that 
are normal constituents of all organs migrate after trans-
plantation and are replaced by recipient cells of the same 
hematolymphopoietic lineages (1-5). With engraftment, the 
"accepted" organ and the recipient become genetic composites 
in that a trace population of the donor leukocytes survives 
peripherally in lymphoid and nonlymphoid recipient tissues 
(microchimerism) as well as in the allograft. Acute contem-
poraneous graft-versus-host (GVH) and host-versus-graft 
(HVG) immune reactions and the subsequent persistence of 
multilineage microchimerism have been proposed to be es-
sential for successful organ transplantation and the variable 
development of donor-specific nonreactivity (tolerance). 
The quantity and lineage profiles of the passenger leuko-
cytes contained in different kinds of organ grafts strongly 
influences the quantity and lineages of the chimerism found 
in the recipients, the relative strengths of the interactive 
HVG and GVH reactions, graft survival, and graft function 
(5-7). The passenger leukocytes ofthe liver and bone marrow 
cells (BMC), both of which include large numbers of imma-
ture leukocytes and cells of myeloid origin, have been shown 
to be more tolerogenic with a lower risk of graft-versus-host 
disease (GVHD) than the intestinal passenger leukocytes, 
which are rich in mature lymphocytes (5). 
In the experiments reported here, the hypothesis was 
tested that modification of the intestinal passenger leuko-
cytes with ex vivo irradiation and the adjunct infusion of 
donor BMC would improve the control of rejection in a fully 
allogeneic small intestinal transplantation (SITx) model 
without causing GVHD. The irradiation doses were designed 
to eliminate or substantially reduce the mature lymphoid 
elements of the passenger leukocytes, without destroying 
precursor hematopoietic cells and without causing irradia-
tion injury to the intestinal epithelial components. The irra-
diated intestinal grafts were transplanted alone or simulta-
neously with intravenously infused donor BMC. 
The efficacy of these treatments was assessed by recipient 
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and graft survival, recipient weight maintenance, graft his-
topathology, and the quality and quantity of donor leukocyte 
microchimerism in Lewis (LEW)-to-Brown Norway (BN) and 
BN-to-LEW rat strain combinations. We have previously 
shown that the former combination was GVHD prone in that 
recipient animals developed fatal GVHD after SITx under a 
short course of immunosuppression (5-7). Although the lym-
phocyte migration patterns are similar in both strain combi-
nations, BN-to-LEW transplantation is not complicated by 
GVHD. Thus, we were able to examine the effect oftreatment 
strategies on the GVH and HVG immune responses in 
GVHD-prone and GVHD-resistant settings. 
MATERIALS AND METHODS 
Animals 
Inbred male LEW (RTl1) and BN (RTI n) rats (200-250 g) were 
purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN) and 
maintained in laminar-flow, specific pathogen-free animal facilities 
at the University of Pittsburgh. All procedures in this study were 
performed according to the guidelines of the Council on Animal Care 
at the University of Pittsburgh. 
Surgical Procedures 
Under methoxyflurane anesthesia, orthotopic SITx with caval 
drainage was performed from LEW-to-BN and BN-to-LEW strains, 
with previously described methods (6-8). The entire small intestine, 
from the ligament of Trietz to the ileocecal valve, was harvested on 
a vascular pedicle consisting of the superior mesenteric artery with 
a piece of aorta and portal vein. The excised intestinal graft, stored 
in cold lactated Ringer's solution in a 50-ml Falcon tube, was then ex 
vivo irradiated from a 137CS source. The total time to achieve the 
irradiation dose of 10 Gy was 2.5 min. End-to-side vascular anasto-
moses between the graft aorta and the recipient infrarenal aorta, 
and between the graft portal vein and recipient vena cava, were 
performed with 10-0 Novafil suture. The recipient small bowel was 
removed except for a few centimeters of proximal jejunum and distal 
ileum. Enteric continuity was restored by proximal and distal end-
to-end intestinal anastomoses. 
Donor BMC were obtained as reported before (5). The medulla of 
the tibias and femurs were flushed with RPMI, supplemented with 
50 fLg/ml gentamicin (Life Technologies, Grand Island, NY). A total 
of 2.5 x 108 cells, determined to be viable by trypan blue exclusion, 
was intravenously infused into recipients on the day of SITx. The 
dose of BMC (2.5 X 108 ) was selected because it corresponded to that 
obtained from a single donor rat. We previously showed that infusion 
on the day of transplantation with this dose of BMC augmented 
chimerism and improved heart allograft outcome (9, 10). We have 
previously shown that infusion of syngenic (BN) BMC does not hav,e 
any effect on allograft outcome (9). 
Animals were given prophylactic cefamandole nafate (20 mg/day) 
for 3 postoperative days. Tacrolimus (FK506; Fujisawa Pharmaceu-
tical Co., Ltd., Osaka, Japan) was intramuscularly administered to 
recipients at a daily dosage of 1.0 mglkg on days 0-13, 20, and 27. All 
animals were followed for at least 150 days after SITx and some were 
kept as long as 203 days before sacrifice to establish the permanence 
of graft acceptance. No animals that lived 150 days died subse-
quently for reasons other than sacrifice for study purposes. Clinical 
signs of rejection were defined as contiriuous or intermittent diar-
rhea and weight loss. GVHD was clinically defined by cutaneous 
erythema, and by hair and weight loss. Both diagnoses were con-
firmed by histopathological analysis. 
Routine and lmmunohistopathological Analyses 
Histopathological analysis was performed on all animals including 
those surviving 2::150 days and those that died prematurely. Graft 
jejunum and ileum including Peyer's patches (PP), mesenteric lymph 
nodes (MLN), and recipient tissues were fixed in formalin, embed-
ded, cut in 6-ILm sections, and stained with hematoxylin and eosin. 
The histopathological changes of the intestinal grafts and native 
intestines were evaluated in a blinded fashion. The degree of epithe-
lial injury was determined by conventional histopathologic criteria 
and by the frequency of apoptosis in crypt epithelial cells. The extent 
and nature of inflammation in the intestine and the presence of 
mesenteric fibrosis in MLN were separately recorded as either 
present or absent. The number of germinal centers in the intestine 
was counted and expressed as the number per section. Severity of 
mesenteric arteriopathy was semiquantitatively graded as 0 (none), 
1 (mild), and 2 (severe). 
Another portion of each sample was snap-frozen in OCT compound 
and sectioned at 4 fLm for immunohistochemical stain using a rou-
tine indirect avidin-biotin complex method as previously described 
(9). BiQtinylated monoclonal antibody (mAb) L21-6 (mouse IgG1), 
which is specific for MHC class II antigens on LEW but not BN (11), 
was applied to differentiate donor MHC class II+ cells in the tissue 
obtained after LEW-to-BN SITx. 
Flow Cytometry 
Recipient peripheral blood. Percentages of donor and recipient 
hematolymphoid cells were sequentially determined by flow cytom-
etry in recipient peripheral blood after lysis of red blood cells. LEW 
and BN cells were identified with affInity-purified biotinylated rat 
mAbs 163 (rat IgG2b) and 42 (rat IgG2a) (from Dr. Heinz Kunz, De-
partment of Pathology, University of Pittsburgh), which are specific for 
the RT1.N (MHC class I) antigen on LEW and the RT1.An antigen on 
BN, respectively (12). Phycoerythrin-conjugated streptavidin (PharM-
ingen, San Diego, CAl was used as a secondary antibody. Cells were 
analyzed using Coulter Elite ESP (Coulter Corp., Miami, FL). 
Allografts. MLN lymphocytes were isolated by injecting RPMI 
into MLN and by filtration through nylon mesh. Lymphocytes in the 
PP were obtained as previously described (6). After the mucosal layer 
of the intestine was disrupted, PP were excised, cut into small pieces, 
digested in a water bath for 30 min at 37°C with RPMI containing 
0.05% collagenase (type B; Boehringer Mannheim, Mannheim, Ger-
many), 10 roM HEPES (Life Technologies), 50 fLg/ml gentamicin, and 
2% fetal bovine serum (Life Technologies), and then passed through 
nylon mesh to separate the remaining connective tissue fragments 
from the lymphocyte fraction. Isolated cells were washed twice with 
RPM! containing 5% fetal bovine serum, 10 mM HEPES, and 50 
fLg/ml gentamicin, 'and further purified by centrifugation over Ficoll-
Paque (s.g. 1.077; Biotech AB, Uppsala, Sweden). The interface was 
collected and washed twice with Hanks' balanced salt solution con-
taining 1 % bovine serum albumin and 0.1% sodium azide (Sigma, St. 
Louis, MOJ. 
Phenotypes and lineages of lym phocytes in the graft MLN and PP 
were determined with two-color flow cytometry using mAbs 163 and 
42; and fluorescein-conjugated lineage-specific mAbs, including R7.3 
(a{3TCR), W3/25 (CD4), OX8 (CD8), OX33 (B cells), and 3.2.3 (natu-
ral killer cells) (all from PharMingenl. Isotype-matched nonspecific 
antibodies were substituted for the primary reagents in the negative 
controls. 
Statistical Analyses 
Comparison of animal survival days between groups was made 
with Wilcoxon rank-sum test. Data in histopathology and flow cy-
tometry were shown as mean :t SD and analyzed by one-way anal-
ysis of variance, Fisher's PLSD test, and Student's t test. Statistical 
significance was established at P<0.05. 
RESULTS 
Effects of Different Irradiation Doses in Syngenic SITx 
LEW recipients received syngenic LEW intestine after 
variable doses of graft irradiation. Long-term adverse effects 
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FIGURE 1. Effect of different dosages of ex vivo graft irradia-
tion on mean body weight gain of LEW recipients of synge-
neic intestinal grafts compared with recipients of nonirradi-
ated grafts and non operated controls. Growth retardation 
was seen only after 20 Gy (2000 rad). 
were assessed by animal growth (i.e., body weight) and graft 
histopathology. Using escalating doses from 0 to 15 Gy ex 
vivo graft irradiation, rates of body weight gain after SITx 
were no different from nonirradiated controls. There was 
evidence of a malnutrition, however, in animals whose grafts 
were exposed to 20 Gy (Fig. 1). 
No specific histopathological changes attributable to radi-
ation were found in the intestine from rats sacrificed between 
150 and 300 days after transplantation. Epithelia and crypts 
were intact in all animals, with only rare apoptotic bodies 
(0-2 cells per 10 crypts), even in intestine subjected to 20 Gy. 
Arterial changes including inflammation, atherosclerosis, or 
thrombosis were not seen in grafts irradiated with 10 or 15 
Gy. Vacuolization of smooth muscle in the mesenteric arter-
ies was minimally increased in grafts subjected to 10 and 15 
Gy, but this also was found in nonirradiated grafts. When 
grafts were irradiated with 20 Gy, the smooth muscle vacu-
olization was noticeably increased, and one animal had mild 
atherosclerosis and fibrosis in the arterial media. Based on 
these data, ex vivo irradiation at a dose of 10 Gy was selected 
for the following allotransplantation experiments. 
Animal Survival, Graft Histopathology, and Chimerism in 
Allogenic SITx 
LEW-to-BN transplantation. Survival: Untreated BN re-
cipients rejected LEW allografts after a median of 11.5 days 
(group 1, Table 1). As previously reported (5-7), all of the 
tacrolimus-treated control recipients died of GVHD with a 
median survival of 51 days (group 2). Death of some animals 
in this group was associated with pneumonia. Tacrolimus-
treated recipients of unmodified intestinal grafts who were 
given adjunct donor BMC (group 3) also died of GVHD after 
a slightly longer survival (median 63 days), but the difference 
from group 2 was not statistically significant (P=0.068). 
Graft irradiation (10 Gy) prevented GVHD in all rats of 
group 4 and prolonged median survival to 92.5 days (range 70 
to 134), but all died of nutritional failure. In contrast, five of 
six recipients of irradiated intestine plus adjunct donor BMC 
(group 5) survived> 150 days without GVHD (Table 1); the 
exceptional animal began to lose weight at 100 days and died 
at 135 days. 
Nutrition: The body weight changes correlated well with 
survival (Fig. 2). Weight gain of tacrolimus-treated BN re-
cipients of nonirradiated (group 2) as well as nonirradiated 
allografts with adjunct donor BMC (group 3) was interrupted 
with the development ofGVHD, followed by rapid weight loss 
and death, Recipients of irradiated intestine (group 4) 
steadily gained weight for about 2 months, but they devel-
oped periodic diarrhea thereafter and lost body weight until 
death. In contrast, four of the six BN recipients of irradiated 
intestine and adjunct donor BMC (group 5) maintained nor-
mal weight for 150 days. 
Histopathology: Low-grade apoptosis, ranging from 0 to 5 
cells per 10 crypts, was found in all LEW intestinal allografts 
(Table 2 and Fig. 3A). The allografts were intact in the group 
2 and 3 animals that died from GVHD after 41-70 days. One 
of the five intestinal allografts in group 4 and three ofthe six 
in group 5 contained significant foci of mural inflammation 
(Table 2 and Fig. 3B [arrow]), comprised mostly ofhistiocytes 
and numerous eosinophils. These foci were located primarily 
in the muscularis propria and seemed to follow penetrating 
branches of vessels. The intestinal inflammation was unlike 
that seen in uncontrolled acute rejection. It also was found to 
a lesser degree in the remnants of recipient bowel. 
In the nonirradiated allografts of the tacrolimus-treated 
recipients dying of GVHD (groups 2 and 3), the intact PP and 
MLN were well populated. Loss of lymphoid cells and an 
increase of fibrotic changes were prominent in the PP and 
MLN of the irradiated grafts of group 4, findings attributable 
to chronic rejection (13). These abnormalities were not 
present or were not severe in the intestinal allografts of 
group 5 that had been transplanted in conjunction with do-
nor BMC (Table 2 and Fig. 3C). Severity of arteritis was 
TABLE 1. Recipient survival after LEW-to-BN and BN-to-LEW intestinal transplantation 
Group Graft irradiation (Gy) Donor BMC (XI08 ) 
LEW-to-BN 
1 0 0 
2 0 0 
3 0 2.5 
4 10 0 
5 10 2.5 
BN-to-LEW 
6 0 0 
7 0 0 
8 10 0 
9 10 2.5 
"Tacrolimus: 1.0 mg/kg/day on days 0-13, 20, and 27. 
Bold number: severe and fatal GVHD. 
-
---
Tacrolimus" N Survival (days) Median (days) 
No 6 11, 11, 12, 12, 13, 13 11.5 
Yes 5 41,46, 51, 55, 55, 51.0 
Yes 5 48,52,63,65,70 63.0 
Yes 6 70,84,92,93,98,134 92.5 
Yes 6 135, >150x5 >150 
No 6 9,9,10,11,12,14 10.5 
Yes 6 >150 x6 >150 
Yes 5 >150 x5 >150 
Yes 5 >150 x5 >150 
aq 
--
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FIGURE 3. Irradiated LEW allografts (all 10 Gy) in different experimental groups. (A) Group 4 Epo~toperative day [POD] 84), 
without adjunct BMC: lower crypts. Occasional crypt cell apoptosis was seen (arrow) (original magnification x20). (B) Group 
5 (POD 157), with adjunct BMC: the mucosal architecture is unremarkable, but focal mural inflammation is evident (arrow) 
without obvious infectious etiology. A less severe similar lesion was seen in the residual recipient bowel (x4). Inset: higher 
power view of the muscularis inflammation, which was comprised primarily of mononuclear cells and eosinophils (x 10). (C) 
Group 5 (POD 203) with adjunct BMC: well-developed PP were more frequently observed in this group (upper intestinal strip) 
than in the non-BMC group 4 (lower intestinal strip, POD 70) (x 5). Inset: higher power view of the marked PP (x 10). (D) Group 
4 (POD 92), without adjunct BMC: arteriopathy of a mesenteric artery branch including smooth muscle vacuolization and 
arteritis, which begins as mononuclear inflammation within the intimal layer (endothelialitis) (x20). 
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significantly increased in the MLN of the irradiated allo-
grafts of group 4 animals compared with that of group 5 with 
adjunct donor BMC (Table 2 and Fig. 3D). Smooth muscle 
vacuolization was not increased over that seen in nonirradi-
ated isografts at comparable times, and no evidence of other 
arterial injury such as atherosclerosis or smooth muscle fi-
brosis was seen in any of the irradiated grafts. 
Comparison in the tacrolimus-treated groups 2-5 of the 
histopathologic findings in the allografts, and particularly of 
vascular abnormalities that might be attributed to the ex 
vivo irradiation in groups 4 and 6, was made difficult by the 
different posttransplantation times of specimen procurement 
at death or sacrifice: about 2 months in group 2, 3 months in 
group 4, and 5 months or beyond in group 5. Consequently, 
nine additional experiments were performed with the group 
6 protocol, except that the weekly doses of tacrolimus were 
continued instead of being discontinued after posttransplan-
tation day 27. Four animals were sacrificed at 60 days, and 
the other 6 at 150 days. There were no arterial changes in 
any of the allografts (Table 2), which had nearly normal PP 
and MLN that were well populated with leukocytes. The 
protection by immunosuppression suggested that the vascu-
lar lesions were largely due to rejection. 
Recipient chimerism: High percentages of donor cells in 
recipient blood were associated with rampant GVHD and the 
death of all tacrolimus-treated BN recipients of unaltered 
LEW intestine grafts whether or not adjunct BMC was given 
(Groups 2 and 3, Table 3). Although the BMC-augmented 
animals of group 3 lived longer and had marginally greater 
chimerism, the clinical courses were much the same. 
the 27-day course of tacrolimus developed GVHD, and all 
survived for 160 days after SITx (Table 1, groups 7-9) with-
out regard for graft irradiation alone or in combination with 
donor BMC infusion. 
Histopathology: The BN intestine allografts were intact in 
groups 7-9, and apoptosis was seen in less than 2 cells per 10 
crypts (Table 2). The mural inflammation found in LEW 
grafts transplanted into BN recipients was not seen in this 
combination. The most normal allografts were those of group 
9 that had been irradiated and were transplanted in conjunc-
tion with adjunct BMC. In addition to well-preserved overall 
architecture, the MLN and PP in the allografts of group 9 
were filled with lymphocytes and had a better score for lym-
phoid contents than either the unaltered grafts of group 7 or 
the irradiated grafts of group S. Irradiated intestinal allo-
grafts without adjunct BMC (group 8) showed the most se-
vere histopathological abnormalities including increased in-
cidence of MLN fibrosis and arterial inflammation. Arteritis 
in group S was more severe than in group 7 (P<O.OOl). 
Arteritis was slightly enhanced in group 9 relative to the 
control allografts of group 7; however, the difference did not 
reach statistical significance (P=O.123). 
Cell Constituency of Graft MLN and PP 
In both the LEW ---c> BN and BN ~ LEW models, the 
rapidity and completeness of leukocyte replacement in the 
MLN and PP were increased by intestinal irradiation alone 
or with adjunct BMC (Fig. 5). With both strain combinations, 
the repopulating recipient leukocytes in graft MLN and PP 
included CD4 +, CDS +, B, and natural killer cells, in propor-
tions similar to those in normal animals of the donor and Donor phenotype cells remained at low but stable levels 
after transplantation under tacrolimus of grafts irradiated 
with 10 Gy (group 4). When the recipients of irradiated 
intestine also were administered adjunct donor BMC (group 
5), stable chimerism was maintained in those GVHD-free 
animals at about twice the l';vel as in group 4 (Table 3). 
Chimerism in the tissues of the group 5 recipients was con-
firmed by immunohistochemical stain with the L21-6 mAb 
that identified donor (LEW) MHC class II-positive cells (Fig. 
4). 
. recipient strains, except for a higher percentage of B cells. 
BN-to-LEW transplantation. Survival: Although the BN 
intestinal allografts invariably were rejected by untreated 
LEW recipients (group 6), none of the recipients treated with 
This is shown in Figure 6 15 days after LEW ~ BN trans-
plantation under the experimental conditions of group 2 (un-
altered intestine and no BMC) and group 5 (intestinal irra-
diation plus adjunct BMC). 
LEW ~ BN transplantation. After 15 days of tacrolimus 
treatment, more donor leukocytes in groups 4 and 5 had been 
replaced by recipient cells than in group 2 (Fig. 5, left panel). 
Compared with the MLN, the replacement was somewhat 
retarded in the PP (Fig. 5, left panel, bottom). 
BN ~ LEW transplantation. Because the cell exchange 
previously had been demonstrated by immunohistochemistry 
TABLE 2. Histopathological findings of allograft intestine and MLN 
Intestine MLN 
Group Graft irradiation (Gy) Donor BMC (XI08 ) Mural Population of Epithelial apoptosis" inflammationC germinal center Fibrosisc Arteritis 
LEW-to-EN 
2 0 0 0-5 0 2 0 0 
4 10 0 0-5 1/5 0.71::':0.42 414 1.60::':0.89 
5 10 2.5 0-3 3/6 1.27::':1.49 4/6 0.83::':0.68 
5Ab 10 2.5 0-1 1/5 2.20::':0.88 0 0 
BN-to-LEW 
7 0 0 0-1 0 0.60::':0.62 1/4 0.38:!:0.25 
8 10 0 0-1 0 0.05:::0.11 4/5 1.50::':0.71 
9 10 2.5 0-1 0 0.99::':0.96 1/5 1.00::':0.61 
a Apoptosis per 10 crypts. 
b 5A: extra group ofBN recipients (n=9) received 10 Gy irradiated LEW grafts and BMC. They were treated continuously with tacrolimus 
and sacrificed at 60 (n=4) and 150 days (n=5). Results from animals sacrificed at 150 days were shown here and were not significantly 
different compared with those at 60 days. 
C Number of animals with intestinal mural inflammation or MLN fibrosis. 
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TABLE 3. Percentages of donor phenotype cells in the peripheral blood after LEW ..... BN transplantation under short 
course of tacrolimusa 
Group Graft 
Posttransplantation days 
day 7 day 14 day 28 day 42 day 70 day 120 
2 
3 
4 
5 
Intestine 
Intestine + BMC 
Intestine (lO'Gyl 
Intestine (10 Gy)+BMC 
3.5::!:1.5 
8.6::!:3.7b 
0.7±1.2c 
2. I::!: 1.3 
2.3:!: 1.3 
6.6::!:2.2c 
0.4::!:O.3c 
1.4::!:1.4 
3.9:!:2.3 
3.9:!:2.9 
1.2::!:O.6b 
2.2::!:2.0 
3.8:!:2.6 NA 
8.3::!:6.0 NA 
1.2::!:l.O 0.5::!:O.4 
2.2::!:1.2 1.2::!:1.2 
NA 
NA 
0.2 
1.6::!:1.4 
a 1.0 mg/kg/day on days 0-13, 20, and 27. 
b P<O.05 vs. group 2. 
c P<O.OI VB. group 2. 
NA, not applicable. 
FIGURE 4. Microchimerism at POD 157 in 
the tongue of a BN recipient of an irradi-
ated LEW intestine and adjunct BMC 
(group 5). Donor cells (red) are scattered 
among other recipient cells. No evidence 
of epithelial injury indicative of GVHD 
was observed (L21-6 immunoperoxidase 
with aminoethylcarbazole, x20). 
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studies to be complete by 15 days (13), flow cytometry anal-
ysis of the BN allografts was done at 7 days. Even at this 
early time, the majority of leukocytes in the MLN of the BN 
grafts already had become recipient (LEW) (Fig. 5, right 
panel, upper) but not in the PP (right panel, lower). 
DISCUSSION 
Attempts to modify intestinal allografts have been driven 
mainly by the historically rooted conviction that GVHD 
would plague clinical trials. As had been predicted by Bill-
ingham (14), the lethal consequences of GVHD were proved 
by Monchik and Russell (15) in genetically controlled rat 
experiments in which semiallogeneic small bowel was trans-
planted from parent to F 1 hybrid offspring recipients who 
were incapable of rejecting the grafts but were subject to 
their attack. Although the F 1 hybrid rat models emphasized 
the peril of a host-graft immunologic imbalance if this fa-
vored the intestinal graft, such laboratory experiments over-
stated the threat of GVHD to noncytoablated humans. 
GVHD has been shown to be a trivial problem in an extensive 
clinical intestinal transplant experience (16-21) and for that 
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matter in outbred large animal models (22-26) unless the 
recipient is cytoablated (27). 
A similarly distorted impression of the risk from GVHD is 
obtained from the LEW ~ BN intestinal transplantation 
model used for many of the experiments reported here, our 
previous studies (5, 6, 28), and those of Foster et a1. (29). The 
fully allogeneic LEWIBN rat strain combination used in our 
experiments had unusual advantages for examination of the 
HVG and GVH components of the double immune reaction 
that follows intestinal and all other kinds of transplantation 
(5). The distinction of donor from recipient leukocytes in 
tissues and blood can be made precisely because of the avail-
ability ofthe L26-6 mAb that densely stains class II+ cells of 
almost all rat strains including LEW, but not those of BN 
(11). 
The failure of BN cells to stain apparently is due to an 
abnormality of the invariant chain. Inefficient antigen pre-
sentation due to the abnormality has been postulated to be 
the explanation for the universal donor status (i.e., low re-
sponse inducer) of this strain (6, 11). Possibly related to the 
same abnormality, the BN rat is highly susceptible to GVHD 
" ! 
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FIGURE 5_ Percentages of donor and recipient cells in graft 
MLN and PP: (Left panel) 15 days after LEW ..... EN intestinal 
transplantation; (Right panel) 7 days after EN -> LEW trans-
plantation. Note that the replacement was more rapid in the 
irradiated grafts without or with adjunct BMC than in the 
nonirradiated grafts and that it occurred more slowly in PP 
than in MLN under all the experimental conditions of groups 
2,4,5,7 and 9. n=3 for all experiments. 
(5-7) allowing this usually invisible limb of the two-way 
immune reaction to be exposed for investigation (5), as in 
parent to defenseless offspring F 1 hybrid models. It has been 
established unequivocally (15,30) and confirmed herein that 
the GVHD that develops after intestinal transplantation in 
immunologically "unbalanced" donor/recipient combinations 
can be readily circumvented by graft irradiation. This objec-
tive also can be met by pretreating the donor with antilym-
phocyte serum (31, 32), but only when donor animals were 
pretreated for 48 hr before harvesting intestinal grafts. Ex 
vivo graft infusion with antilymphocyte serum failed to pre-
vent GVHD (31). Because this study was designed to fit a 
clinical setting in which pretreatment of donor with antilym-
phocyte serum or similar mAbs for 48 hr usually is not 
possible, ex vivo irradiation was chosen as the method to 
modify intestinal allografts. 
The tacrolimus-treated BN rats in our experiments who 
received unaltered LEW intestine alone or in conjunction 
with donor bone marrow (experimental groups 2 and 3) all 
died of GVHD after 41-70 days. Interestingly, the addition of 
infused donor BMC to the passenger leukocyte load of the 
intestine did not demonstrably intensify the GVHD, a previ-
ously unpublished observation that justified the initiation in 
1995 of clinical protocols of adjunct BMC for intestinal and 
multivisceral recipients (20, 21, 33). It is noteworthy that at 
the time of recipient death from GVHD, the transplanted 
intestinal grafts were intact with well-preserved MLN and 
PP (i.e., gut-associated lymphoid tissue [GALT]). 
As expected, the GVHD in the LEW ~ BN model was 
completely avoided by irradiating the LEW intestine of the 
group 4 BN recipients. However, all of the animals died after 
70-134 days of nutritional insufficiency caused by chronic 
bowel rejection that included involution and disappearance 
of the GALT. The persistence of very low level microchimer-
ism in these animals was consistent with the survival of a 
subset of radiation-resistant stem cells that has been de-
scribed many times over the last 40 years (reviewed by Hen-
dry and Lord [34]) but demonstrated convincingly only since 
1990 (35-37). However, the number of the passenger leuko-
cytes in the recipients of irradiated bowel apparently was 
reduced below the threshold necessary to acutely induce the 
donor-specific clonal exhaustion-deletion that is the seminal 
basis of organ allograft acceptance and acquired tolerance (1, 
2, 4). The same antitolerogenic effect is caused by lethal 
whole body irradiation of the donor (38). Ko et a1. (39) have 
recently demonstrated the same principle, by administering 
a donor leukocyte-specific antibody to the recipient on the 
day of rat heart transplantation. 
In contrast, a long period of immunosuppression-free sur-
vival of BN recipients of irradiated LEW allografts was reg-
ularly accomplished by infusing 2.5 X 108 adjunct donor BMC, 
analogous to restoration of the tolerogenicity of leukocyte-
depleted liver allografts by repletion of hepatic passenger 
leukocytes (40, 41). Failure of the large dose ofBMC to cause 
the GVHD regularly produced by the intestinal passenger 
leukocytes in the LEW ~ BN model was explained by the 
differences in the lineage constituency of the two leukocyte 
populations and the state of maturation of the lineages (5). 
Such experiments have demonstrated both by positive and 
negative example that the penalty for passenger leukocyte 
depletion, without substitution of the alternative supply of 
mobile donor cells required for clonal exhaustion-deletion, is 
erosion of the seminal mechanisms of engraftment (1, 2, 4). 
Conversely, replacement of the intestinal leukocytes lost to 
ex vivo irradiation by immature donor BMC was able to alter 
both the GVH and HVG immune reactions in a favorable 
way. As described in detail elsewhere, the mechanisms by 
which this was accomplished involve an antigen-specific dou-
ble immune reaction (HVG and GVH), no different in princi-
ple with the intestine than with transplanted solid organs 
(1-6). The distribution of the donor leukocytes between the 
recipient lymphoid and nonlymphoid tissues, blood, and the 
allograft itself rapidly changes in a time-dependent manner 
as described in detail (10, 42, 43) and summarized elsewhere 
(4). 
The adverse effect of ex vivo irradiation on tolerogenesis 
was most unequivocally shown when the intestinal trans-
plantation was done with the BN ~ LEW model in which the 
confounding factor of GVHD was not present. All of the 
tacrolimus-treated LEW recipients survived ::2:150 days in 
good condition but, as previously reported (13), moderate 
chronic rejection including damage to the GALT structures 
(MLN and PP) was found despite tacrolimus in the nonirra-
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diated allografts of group 7. These changes were far more 
advanced, however, in the irradiated allografts ofthe tacroli-
mus-treated animals of group 8. In contrast, there was es-
sentially no evidence of rejection in the irradiated allografts 
that had been transplanted with adjunct BMC to tacrolimus-
treated recipients (group 9). 
Although the best results in both the LEW ~ BN and BN 
~ LEW models were obtained with the combination of bowel 
irradiation and BMC infusion, the possibility of subtle dam-
age to the intestine from ex vivo irradiation, taking months 
or years to develop, was not ruled out in these experiments, 
even at the seemingly conservative dose of 10 Gy that also is 
thought to be safe for dog (24), pig (44), and presumably 
human intestine. Direct damage to the endothelial cells has 
been proposed to be the chief mechanism of irradiation dam-
age (45, 46) ultimately leading to destruction of the microcir-
culation. The findings of radiation vasculopathy are dose and 
time dependent. They include subendothelial connective tis-
sue proliferation, disruption of the elastic lamina, accumula-
tion of intimal and subintimal fibrinoid substances, degener-
ation of smooth muscle, dense fibrosis of the adventitia, 
aggregation of foamy histiocytes in the damaged wall, and 
obliteration of vasa vasorum (45-47). 
Local or regional radiotherapy for malignant neoplasms, 
with maximum tolerated doses (usually exceeding 20 Gy), is 
the usual cause of the radiation vasculopathy. Since ex vivo 
irradiation is considered to be less harmful than irradiation 
of tissues with blood circulation, the 10 Gy dose used in our 
experiments cannot be considered comparable to the dosages 
in the oncology studies. In the context of transplantation, 
however, vasculopathy of small muscular arteries has been 
described in recipients of allogenic bone marrow transplan-
tation conditioned by total body irradiation (48). In addition 
to the irradiation, the complication has been attributed to 
multiple factors (e.g., immune activation, immunosuppres-
8 
10 
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BN 
OX33+ D CD8+ 0 CD4+ • NK-RP1+ 
sion, infection, GVHD) (48). Combined with these alloimmu-
nity-associated factors, all of which are operational in the 
organ recipient, it is theoretically possible that an otherwise 
inconsequential dose of ex vivo irradiation could become 
significant. 
Thus, although it was reassuring that 10 Gy irradiation of 
syngeneic bowel (isografts) caused no demonstrable impair-
ment of weight gain or histopathologic changes, the finding of' 
slight but consistent increases of arteritis in the irradiated 
intestine of both the LEW ~ BN and BN -i> LEW models was 
disquieting. Consequently, additional experiments were per-
formed, using the same protocol as in group 5 (i.e., intestinal 
irradiation plus adjunct BMC) except that weekly doses' of 
tacrolimus were continued throughout the 150 days of obser-
vation instead of stopping at day 27. The arterial changes 
were completely prevented, establishing an alloimmune eti-
ology of the vasculitis. However, they did not conclusively 
eliminate the possibility of an irradiation cofactor. 
Collectively, the studies reported herein illustrate how in-
sight into the mechanisms of allograft acceptance and toler-
ance can help devise realistic clinical strategies to improve 
organ transplantation. The insight began to evolve a decade 
ago with observations of intestinal passenger leukocyte mi-
gration and replacement (6, 13, 28) that quickly matured to 
the definition of all transplantation outcomes in terms of a 
double immune reaction (HVG and GVH) (1-5). The role of 
intestinal transplantation in the evolution was an important 
one because th.e two immune responses could be so easily 
studied separately in models like those of the present report. 
At the beginning of this period, intestinal transplant confer-
ences were dominated by studies of lymphoid depletion by a 
variety of methods (22, 24, 29-32, 44), even including me-
chanical removal of all accessible lymphoid tissue. At a prac-
tical level, it was soon learned that avoidance of the GVH 
reaction was not needed in most experimental intestinal 
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transplantation models or clinically. The current experi-
ments show how such depletion of the host-reactive passen-
ger leukocytes is overtly inimical to long-term intestinal graft 
survival unless an alternative leukocyte source is provided. 
With all organ·s, the key objective is provision of a large 
enough volume of optimally immunogenic/tolerogenic donor 
leukocytes to induce some level oftolerance, even though this 
requires an umbrella of immunosuppression and is incom-
plete (1, 2, 4). This objective can be partly accomplished by 
infusing adjunct BMC as has been done safely in current 
clinical trials (20, 21). This study demonstrates further active 
modification of the intestinal leukocyte composition is advan-
tageous. A further search for methods to do this other than 
with ex vivo irradiation would be considered because of the 
difficulty of eliminating with absolute certainty the possibil-
ity of radiation-associated vasculopathy. 
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ISLET ALLOGRAFT REJECTION CAN BE MEDIATED BY CD4+, 
ALLOANTIGEN EXPERIENCED, DIRECT PATHWAY T CELLS OF 
THI AND TH2 CYTOKINE PHENOTYPE l 
JEFFREY A. J. BARBARA, STUART E. TURVEY, CHERRY 1. KINGSLEY, BERND M. SPRIEWALD, 
MAsAKI HARA, OLIVER WITZKE, PETER J. MORRIS, AND KATHRYN J. WOOD2 
Nuffield Department of purg~ryI University of Oxford, The John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK 
Background. It is widely believed that Thl cells that 
secrete interferon-" are primarily involved in the re-
jection of allografts whereas Th2 cells [interleukin(lL) 
4 and IL-IO] are thought to be protective of this pro-
cess. However, the exact role and specificity of these 
helper T lymphocytes in mediating allograft damage is 
presently unknown. . 
Methods. ThO, Thl, and Th2 cell lines specific for the 
class II MHC molecule H2IAb were adoptively trans-
ferred into T cell deficient, syngeneic, diabetic mice 
before transplantation of fully allogeneic C57BUIO 
(H2b) or (CBKxBALB/c)Fl (H2k1d +Kb) islet grafts. T 
cells were 5-(and-6-)-carboxyfluorescein diacetate suc-
cinimidyl ester- (CFSE) labeled to allow detection, im-
munohistochemistry was performed, and IL-4 tran-
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scripts within the rejected islet grafts were quantified 
by reverse transcriptase polymerase chain reaction 
(RT-PCR). 
Results. Adoptive transfer (IV) of ThO-, Thl-, and Th2 
lAb-specific T cells resulted in rejection of H2b islet 
allografts. CFSE-Iabeling demonstrated that these T 
cells were able to home to the graft site. CD4 + T cells 
and CDllb+ macrophages were present within the 
graft after adoptive transfer of both Thl and Th2 cells. 
Interestingly, CDS+ T cells and B cells were absent 
from these rejecting grafts. Even when Th2 cells were 
introduced directly at the graft site, prompt rejection 
was still observed despite the presence of increased 
IL-4 mRNA expression within the islet allografts. 
Conclusions. Th2 and ThO alloreactive CD4 + T 
helper cells can reject islet grafts with similar effi-
ciency to Thl cells. These results suggest that devia-
tion of the immune response from a Thl to Th2 pheno-
type will not be sufficient to allow successful 
engraftment of allogeneic organs or tissues. 
T cells playa definitive role in allograft rejection as dem-
onstrated by the inability of neonatally thymectomized and 
